Korean Development For Harvard Impotence Treatment

31 March 1996

- Harvard Scientific has signed its first licensing agreement, with Sae Han Pharmaceuticals, over rights to distribute Harvard's prostaglandin E1-based erectile dysfunction product in Sae Han's home market, Korea. Harvard is seeking to enter into a series of these agreements worldwide. Sae Han plans to begin Phase II/III studies shortly in up to 600 patients. Harvard expects to begin shipping approximately 15,000 units per month to Sae Han in January 1997.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight